I Peace Revolutionizes iPSC Development with Low Immunoreaction Risk Products for Therapies I Peace Inc. has launched new GMP iPSCs derived from type O female blood, reducing immunoreaction risk and enhancing cell therapy potential.

I Peace Revolutionizes iPSC Development with Low Immunoreaction Risk Products for Therapies #United_States #Palo_Alto #iPS_Cells #GMP_Cells #I_Peace